Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Nanoparticles are heterologous small composites that are usually between 1 and 100 nanometers in size. They are applied in many areas of medicine with one of them being drug delivery. Nanoparticles have a number of advantages as drug carriers which include reduced toxic effects, increased bioavailability, and their ability to be modified for specific tissues or cells. Due to the exciting development of nanotechnology concomitant with advances in biotechnology and medicine, the number of clinical trials devoted to nanoparticles for drug delivery is growing rapidly. Some nanoparticles, lipid-based types, in particular, played a crucial role in the developing and manufacturing of the two COVID-19 vaccines—Pfizer and Moderna—that are now being widely used. In this analysis, we provide a quantitative survey of clinical trials using nanoparticles during the period from 2002 to 2021 as well as the recent FDA-approved drugs (since 2016). A total of 486 clinical trials were identified using the clinicaltrials.gov database. The prevailing types of nanoparticles were liposomes (44%) and protein-based formulations (26%) during this period. The most commonly investigated content of the nanoparticles were paclitaxel (23%), metals (11%), doxorubicin (9%), bupivacaine and various vaccines (both were 8%). Among the FDA-approved nanoparticle drugs, polymeric (29%), liposomal (22%) and lipid-based (21%) drugs were the most common. In this analysis, we also discuss the differential development of the diverse groups of nanoparticles and their content, as well as the underlying factors behind the trends.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586 · cited 2×
“The authors point out that, due to the significant diversity of nanoparticles, in the future, trends are likely to shift towards newer types of nanoparticles [30].”
BackgroundThe History of Nanoscience and Nanotechnology: From Chemical–Physical Applications to Nanomedicine
Bayda, S., Adeel, M., Tuccinardi, T., Cordani, M., & Rizzolio, F. (2019) · Molecules · doi:10.3390/molecules25010112 · Cited by 2,016 · cited 1×
“All currently existing diseases can be described in terms of changes at the molecular level, which served as one of the incentives for the development of nanomedicine [1].”
BackgroundNanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766 · cited 1×
“A more recent 2019 review notes the emergence of a new trend in the use of nanoparticles as a way to deliver mRNAs [31].”
BackgroundProgress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 1,352
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321 · cited 2×
“They also note that 28 of these studies were focusing on lipid-based nanoparticles (25 trials out of 28 were mRNA-based vaccines) [33].”
Backgroundvan der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
A review on the classification, characterisation, synthesis of nanoparticles and their application
Anu Mary Ealia, S., & Saravanakumar, M. P. (2017) · IOP Conference Series: Materials Science and Engineering · doi:10.1088/1757-899x/263/3/032019 · Cited by 1,050 · cited 3×
“based on the previously published literature [17,18].”
BackgroundMethodIjaz, I., Gilani, E., Nazir, A., & Bukhari, A. (2020) · Green Chemistry Letters and Reviews · doi:10.1080/17518253.2020.1802517 · Cited by 992 · cited 3×
“based on the previously published literature [17,18].”
BackgroundMethodEnhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Cancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
Liposome composition in drug delivery design, synthesis, characterization, and clinical application
Large, D. E., Abdelmessih, R. G., Fink, E. A., & Auguste, D. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113851 · Cited by 877 · cited 2×
“Liposomes are specific spherical vesicles, chemically similar to cell membranes and are characterized by a low frequency of allergic reactions and systemic toxicity in response to ingestion [24].”
BackgroundTrends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Self-citationSafra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., Henderson, R., Berry, G., & Gabizon, A. (2000) · Annals of Oncology · doi:10.1023/a:1008365716693 · Cited by 618 · cited 1×
“One of the possible directions is the use of liposomal formulations as a replacement for existing drugs to reduce toxic effects (for example, Doxil significantly reduces cardiotoxicity compared to conventional doxorubicin) [43].”
BackgroundPolymeric nanoparticles: Promising platform for drug delivery
El-Say, K. M., & El-Sawy, H. S. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.052 · Cited by 608
Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., & López-Romero, J. M. (2019) · Nanomaterials · doi:10.3390/nano9040638 · Cited by 527
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Nanomedicine review: clinical developments in liposomal applications
Beltrán-Gracia, E., López-Camacho, A., Higuera-Ciapara, I., Velázquez-Fernández, J. B., & Vallejo-Cardona, A. A. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0055-y · Cited by 513
Magnetic nanoparticles in nanomedicine: a review of recent advances
Wu, K., Su, D., Liu, J., Saha, R., & Wang, J.-P. (2019) · Nanotechnology · doi:10.1088/1361-6528/ab4241 · Cited by 509 · cited 1×
“The main idea is to control the site-specific delivery of such nanoparticles just by using the magnetic field [21,22].”
BackgroundAcylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000408 · Cited by 507
Self-citationObstacles and opportunities in a forward vision for cancer nanomedicine
de Lázaro, I., & Mooney, D. J. (2021) · Nature Materials · doi:10.1038/s41563-021-01047-7 · Cited by 439
Bhatia, S. N., Chen, X., Dobrovolskaia, M. A., & Lammers, T. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00496-9 · Cited by 406
Delivering the power of nanomedicine to patients today
Germain, M., Caputo, F., Metcalfe, S., Tosi, G., Spring, K., Åslund, A. K. O., Pottier, A., Schiffelers, R., Ceccaldi, A., & Schmid, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.007 · Cited by 405
Nanoparticles and its biomedical applications in health and diseases: special focus on drug delivery
Zahin, N., Anwar, R., Tewari, D., Kabir, M. T., Sajid, A., Mathew, B., Uddin, M. S., Aleya, L., & Abdel-Daim, M. M. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-05211-0 · Cited by 371
Magnetic Iron Oxide Nanoparticle (IONP) Synthesis to Applications: Present and Future
Ajinkya, N., Yu, X., Kaithal, P., Luo, H., Somani, P., & Ramakrishna, S. (2020) · Materials · doi:10.3390/ma13204644 · Cited by 362 · cited 1×
“The main idea is to control the site-specific delivery of such nanoparticles just by using the magnetic field [21,22].”
BackgroundNanomedicine and drug delivery: a mini review
Mirza, A. Z., & Siddiqui, F. A. (2014) · International Nano Letters · doi:10.1007/s40089-014-0094-7 · Cited by 353 · cited 1×
“The use of nanoparticles as drug carriers has enabled the improvement in drug kinetics, for example, by increasing the circulation time and modulating the interactions between tissues and the drug [16].”
BackgroundNanoparticles in the clinic: An update post COVID‐19 vaccines
Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10246 · Cited by 337 · cited 1×
“The authors explain the reason for this popularity with the success of FDA-approved Abraxane and Doxil, which were the majority of nanoparticles in clinical trials by the time the work was published [32].”
BackgroundLipid-Based Nanoparticles for Drug Delivery Systems
Samimi, S., Maghsoudnia, N., Eftekhari, R. B., & Dorkoosh, F. (2019) · Characterization and Biology of Nanomaterials for Drug Delivery · doi:10.1016/b978-0-12-814031-4.00003-9 · Cited by 266
Protein Based Nanostructures for Drug Delivery
Verma, D., Gulati, N., Kaul, S., Mukherjee, S., & Nagaich, U. (2018) · Journal of Pharmaceutics · doi:10.1155/2018/9285854 · Cited by 244 · cited 1×
“Protein nanoparticles also offer an opportunity for the oral administration of peptides loaded in nanoparticles, for example, NPs loaded with insulin [42].”
BackgroundMicellar Drug Delivery Systems Based on Natural Biopolymers
Atanase, L. I. (2021) · Polymers · doi:10.3390/polym13030477 · Cited by 239
On behalf of the SentiMAG Trialists Group, Douek, M., Klaase, J., Monypenny, I., Kothari, A., Zechmeister, K., Brown, D., Wyld, L., Drew, P., Garmo, H., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3379-6 · Cited by 230
Cancer Targeting and Drug Delivery Using Carbon-Based Quantum Dots and Nanotubes
Pardo, J., Peng, Z., & Leblanc, R. (2018) · Molecules · doi:10.3390/molecules23020378 · Cited by 226
Progress in Polymeric Micelles for Drug Delivery Applications
Kotta, S., Aldawsari, H. M., Badr-Eldin, S. M., Nair, A. B., & YT, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081636 · Cited by 219
Nanoparticles and Vaccine Development
kheirollahpour, M., Mehrabi, M., Dounighi, N. M., Mohammadi, M., & Masoudi, A. (2020) · Pharmaceutical Nanotechnology · doi:10.2174/2211738507666191024162042 · Cited by 195
Recent advances in nanoparticle-mediated drug delivery
Kumar, B., Jalodia, K., Kumar, P., & Gautam, H. K. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.07.019 · Cited by 187
Unger, W. W. J., van Beelen, A. J., Bruijns, S. C., Joshi, M., Fehres, C. M., van Bloois, L., Verstege, M. I., Ambrosini, M., Kalay, H., Nazmi, K., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.007 · Cited by 184 · cited 1×
“Moreover, they could be modified in a way that they become specific to only certain types of cells, for example, dendritic cells [44].”
BackgroundChatzikleanthous, D., O’Hagan, D. T., & Adamo, R. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00447 · Cited by 144
Mamidi, N., & Delgadillo, R. M. V. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111819 · Cited by 128
Carbon quantum dots: A promising nanocarrier for bioimaging and drug delivery in cancer
Jana, P., & Dev, A. (2022) · Materials Today Communications · doi:10.1016/j.mtcomm.2022.104068 · Cited by 125
Regulating trained immunity with nanomedicine
van Leent, M. M. T., Priem, B., Schrijver, D. P., de Dreu, A., Hofstraat, S. R. J., Zwolsman, R. C., Beldman, T. J., Netea, M. G., & Mulder, W. J. M. (2022) · Nature Reviews Materials · doi:10.1038/s41578-021-00413-w · Cited by 123
Soluble ligands as drug targets
Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 120
Self-citationThe use of nanotechnology in cardiovascular disease
Chandarana, M., Curtis, A. D. M., & Hoskins, C. (2018) · Applied Nanoscience · doi:10.1007/s13204-018-0856-z · Cited by 119
Sharifianjazi, F., Irani, M., Esmaeilkhanian, A., Bazli, L., Asl, M. S., Jang, H. W., Kim, S. Y., Ramakrishna, S., Shokouhimehr, M., & Varma, R. S. (2021) · Materials Science and Engineering B · doi:10.1016/j.mseb.2021.115358 · Cited by 113 · cited 1×
“One of the relatively new magnetic systems based on iron nanoparticles showed greater efficacy and imposes less danger compared to traditional methods for assessing sentinel lymph nodes biopsy or other targeted drug delivery [13,14].”
BackgroundDang, D. H., Riaz, K. M., & Karamichos, D. (2022) · Drugs · doi:10.1007/s40265-021-01660-5 · Cited by 106 · cited 1×
“Mucus-penetrating nanoparticles were used in two drug preparations that mainly differed only by the concentration of the drug (Inveltys and Eysuvis, 14%) [38].”
BackgroundQuantum dots as targeted doxorubicin drug delivery nanosystems in human lung cancer cells
Ruzycka-Ayoush, M., Kowalik, P., Kowalczyk, A., Bujak, P., Nowicka, A. M., Wojewódzka, M., Kruszewski, M. K., & Grudziński, I. P. (2021) · Cancer Nanotechnology · doi:10.1186/s12645-021-00077-9 · Cited by 99
Micro and nanosystems for delivering local anesthetics
de Paula, E., Cereda, C. M. S., Fraceto, L. F., de Araújo, D. R., Franz‐Montan, M., Tófoli, G. R., Ranali, J., Volpato, M. C., & Groppo, F. C. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.738664 · Cited by 88
Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review
Cheraghi, M., Negahdari, B., Daraee, H., & Eatemadi, A. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.009 · Cited by 79 · cited 1×
“For example, loading nanoparticles in immune cells as Trojan horses showed better results than regular intravenous administration [48,49].”
BackgroundRecent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders
Zhu, C., Ma, J., Ji, Z., Shen, J., & Wang, Q. (2021) · Molecules · doi:10.3390/molecules26113428 · Cited by 75
Advances of Nanomedicine in Radiotherapy
Liu, W., Chen, B., Zheng, H., Xing, Y., Chen, G., Zhou, P., Qian, L., & Min, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111757 · Cited by 55
Nene, A., Galluzzi, M., Hongrong, L., Somani, P. R., Ramakrishna, S., & Yu, X. (2021) · Nanoscale · doi:10.1039/d1nr01851e · Cited by 52 · cited 1×
“For instance, silver nanoparticles were found to display greater dispersion and stability which renders them as promising candidates in nanomedicine [20].”
BackgroundHawman, D. W., Meade-White, K. D., Archer, J. F., Leventhal, S. S., Wilson, D., Shaia, C., Randall, S., Khandhar, A. P., Krieger, K., Hsiang, T.-Y., et al. (2022) · eLife · doi:10.7554/elife.75537 · Cited by 35 · cited 5×
“List of Abbreviations AIDS acquired immunodeficiency syndrome CE Mark European Conformity Mark EMA European Medicines Agency ESA erythropoiesis-stimulating agent EUA emergency use authorization FDA food and drug administration LION lipid and inorganic nanoparticles MAC Mycobacterium Avium Complex mRNA messenger ribonu…”
BackgroundMethodInfluentialLiang, W., Dong, Y., Shao, R., Zhang, S., Wu, X., Huang, X., Sun, B., Zeng, B., & Zhao, J. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.2023160 · Cited by 26 · cited 1×
“Liposomes have shown remarkable results due to their high bioavailability and relatively low immunogenicity [55].”
BackgroundHou, T., Sana, S. S., Li, H., Wang, X., Wang, Q., Boya, V. K. N., Vadde, R., Kumar, R., Kumbhakar, D. V., Zhang, Z., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102155 · Cited by 21 · cited 1×
“Another prime example of nanomedicine application in oncology might be a newly proposed system of zinc oxide nanoparticles for glioblastoma treatment [9].”
BackgroundThe Big Potential of Small Particles: Lipid-Based Nanoparticles and Exosomes in Vaccination
Shimon, M. B., Shapira, S., Seni, J., & Arber, N. (2022) · Vaccines · doi:10.3390/vaccines10071119 · Cited by 20
Quantum dots as targeted doxorubicin drug delivery nanosystems in human lung cancer cellsPreprint
Ruzycka-Ayoush, M., Kowalik, P., Kowalczyk, A., Bujak, P., Nowicka, A. M., Wojewódzka, M., Kruszewski, M. K., & Grudziński, I. P. (2020) · doi:10.21203/rs.3.rs-37874/v1 · Cited by 15
Targeting strategies of liposomal subunit vaccine delivery systems to improve vaccine efficacy
Yu, R., Mai, Y., Zhao, Y., Hou, Y., Liu, Y., & Yang, J. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1547734 · Cited by 14 · cited 1×
“Liposomes also tend to cause fewer toxic effects than regular drugs, which could be perceived as a propitious area in vaccinology, especially during the COVID-19 period [45].”
BackgroundInnovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control
Yamada, Y., Sato, Y., Nakamura, T., & Harashima, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.033 · Cited by 11
Cited by
New opportunities and old challenges in the clinical translation of nanotheranostics
Gawne, P. J., Ferreira, M., Papaluca, M., Grimm, J., & Decuzzi, P. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00581-x · Cited by 255
Metadata
- Authors
- Namiot, E. D., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-01-02
- Volume
- 24
- Issue
- 1
- Pages
- 787
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4313471826
- Cited by
- 165
- References
- 56
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.